WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2016 after the U.S. markets close on May 9, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s research and development pipeline.
